BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38127829)

  • 21. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
    Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
    Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medullary thyroid carcinoma.
    Pacini F; Castagna MG; Cipri C; Schlumberger M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):475-85. PubMed ID: 20627492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics of medullary thyroid cancer: An overview.
    Accardo G; Conzo G; Esposito D; Gambardella C; Mazzella M; Castaldo F; Di Donna C; Polistena A; Avenia N; Colantuoni V; Giugliano D; Pasquali D
    Int J Surg; 2017 May; 41 Suppl 1():S2-S6. PubMed ID: 28506408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity.
    Zhu W; Hai T; Ye L; Cote GJ
    J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.
    Miyauchi A; Matsuzuka F; Hirai K; Yokozawa T; Kobayashi K; Kuma S; Kuma K; Futami H; Yamaguchi K
    World J Surg; 2000 Nov; 24(11):1367-72. PubMed ID: 11038208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
    Chang CF; Yang WS; Su YN; Wu IL; Chang TC
    J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
    Cerrato A; De Falco V; Santoro M
    J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modifying impact of
    Kaczmarek-Ryś M; Ziemnicka K; Pławski A; Budny B; Michalak M; Hryhorowicz S; Hoppe-Gołębiewska J; Boruń P; Gołąb M; Czetwertyńska M; Sromek M; Szalata M; Ruchała M; Słomski R
    Endocr Relat Cancer; 2018 Apr; 25(4):421-436. PubMed ID: 29386230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
    Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
    Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D
    Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.
    Machens A; Dralle H
    World J Surg; 2007 May; 31(5):957-68. PubMed ID: 17453286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation.
    Machens A; Lorenz K; Weber F; Dralle H
    Eur J Surg Oncol; 2021 Apr; 47(4):920-923. PubMed ID: 32962888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of hereditary medullary thyroid carcinoma.
    Pappa T; Alevizaki M
    Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.